Capricor Therapeutics (NASDAQ:CAPR) Trading 4.3% Higher – Here’s What Happened

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) were up 4.3% during trading on Monday . The company traded as high as $19.87 and last traded at $19.68. Approximately 646,996 shares changed hands during trading, a decline of 43% from the average daily volume of 1,134,629 shares. The stock had previously closed at $18.86.

Analyst Upgrades and Downgrades

A number of analysts have commented on CAPR shares. Maxim Group upped their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $8.00 target price on shares of Capricor Therapeutics in a report on Friday, September 20th. Piper Sandler started coverage on Capricor Therapeutics in a report on Monday. They issued an “overweight” rating and a $35.00 target price on the stock. Oppenheimer reiterated an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a report on Monday, September 23rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Capricor Therapeutics in a report on Wednesday, October 9th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

Capricor Therapeutics Price Performance

The business has a fifty day moving average of $9.70 and a 200 day moving average of $6.71. The stock has a market cap of $684.03 million, a price-to-earnings ratio of -24.61 and a beta of 4.01.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The firm had revenue of $3.97 million during the quarter, compared to analyst estimates of $4.51 million. On average, analysts expect that Capricor Therapeutics Inc will post -1.13 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the firm’s stock in a transaction on Friday, September 20th. The stock was purchased at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 12.00% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets bought a new stake in shares of Capricor Therapeutics in the first quarter valued at approximately $40,000. Main Street Financial Solutions LLC boosted its position in shares of Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after acquiring an additional 7,500 shares during the period. SG Americas Securities LLC bought a new stake in shares of Capricor Therapeutics in the third quarter valued at approximately $133,000. Bank of New York Mellon Corp boosted its position in shares of Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after acquiring an additional 9,040 shares during the period. Finally, Rhumbline Advisers bought a new stake in shares of Capricor Therapeutics in the second quarter valued at approximately $147,000. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.